Orchard Therapeutics PLC
Hanna Kymalainen has extensive experience in the field of research and development. Hanna began their career as a Postdoctoral Researcher at Royal Holloway, University of London in 2012. Hanna then moved on to roles at Autolus Ltd., where they held positions as a Senior Scientist and Senior Scientist II. Most recently, Hanna has been working at Orchard Therapeutics, initially as a Senior Manager and now as a Principal Scientist.
Hanna Kymalainen holds a Bachelor of Science (BSc) in Human/Medical Genetics from UCL, obtained in 2006, followed by a Doctor of Philosophy (PhD) in Gene/Genetic Therapy from Royal Holloway, University of London, completed in 2012. In 2021, they obtained certification in Process Scale-up, Validation, and Technology Transfer for Biologics from Symmetric Training.
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.